WO2007005672A3 - Treatment and prevention of respiratory diseases and conditions - Google Patents
Treatment and prevention of respiratory diseases and conditions Download PDFInfo
- Publication number
- WO2007005672A3 WO2007005672A3 PCT/US2006/025705 US2006025705W WO2007005672A3 WO 2007005672 A3 WO2007005672 A3 WO 2007005672A3 US 2006025705 W US2006025705 W US 2006025705W WO 2007005672 A3 WO2007005672 A3 WO 2007005672A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conditions
- respiratory diseases
- prevention
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides compositions and methods for treating respiratory diseases and conditions. Such compositions and methods utilize a neutral lipid and a phospholipid combined with a lung surfactant polypeptide.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69583005P | 2005-06-30 | 2005-06-30 | |
US60/695,830 | 2005-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007005672A2 WO2007005672A2 (en) | 2007-01-11 |
WO2007005672A3 true WO2007005672A3 (en) | 2007-05-10 |
Family
ID=37521580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/025705 WO2007005672A2 (en) | 2005-06-30 | 2006-06-30 | Treatment and prevention of respiratory diseases and conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007005672A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2562806T3 (en) * | 2007-06-05 | 2016-03-08 | Paka Pulmonary Pharmaceuticals, Inc. | Compositions for administering medications in the lungs, and uses thereof |
AU2009324637B2 (en) | 2008-12-10 | 2016-09-08 | Paka Pulmonary Pharmaceuticals, Inc. | Methods and compositions for delivery of medicaments to the lungs |
WO2010087771A1 (en) * | 2009-01-30 | 2010-08-05 | Alphabeta Ab | Compound and method for treatment of alzheimer's disease |
AU2010356144B2 (en) | 2010-06-24 | 2015-06-04 | Alphabeta Ab | Compound and method for treatment of Alzheimer's disease and familial dementia |
US9522170B2 (en) | 2011-04-05 | 2016-12-20 | Alphabeta Ab | Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein |
WO2013188016A2 (en) * | 2012-05-04 | 2013-12-19 | Discovery Laboratories, Inc. | Surfactant therapy for exposure to ionizing radiation |
US20160235813A1 (en) * | 2013-09-18 | 2016-08-18 | James Cook University | Anti-inflammatory proteins and methods of use |
AU2014324094B2 (en) | 2013-09-18 | 2019-03-14 | James Cook University | Modified anti-inflammatory proteins and method of use |
CN104382942A (en) * | 2014-11-05 | 2015-03-04 | 烟台东诚药业集团股份有限公司 | Novel process for preparing swine pulmonary surfactant suspension |
MX2020011127A (en) * | 2018-04-23 | 2021-01-15 | Chiesi Farm Spa | A therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of bpd. |
CN115414473A (en) * | 2022-08-25 | 2022-12-02 | 中国人民解放军军事科学院军事医学研究院 | Collagenase liposome inhalant and application thereof in treating pulmonary fibrosis |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0406998A2 (en) * | 1989-03-15 | 1991-01-09 | Board Of Regents, The University Of Texas System | Use of phospholipids in lung surfactant replacement therapy |
US5260284A (en) * | 1987-02-17 | 1993-11-09 | Board Of Regents, The University Of Texas System | Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy |
US20020099033A1 (en) * | 1997-04-16 | 2002-07-25 | Wisconsin Alumni Research Foundation | Method and composition for treating sleep apnea |
WO2003035679A2 (en) * | 2001-10-25 | 2003-05-01 | Medical Research Council | Molecules |
WO2003090682A2 (en) * | 2002-04-25 | 2003-11-06 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
WO2005055994A1 (en) * | 2003-12-04 | 2005-06-23 | The Scripps Research Institute | Treatment and preventions of asthma |
-
2006
- 2006-06-30 WO PCT/US2006/025705 patent/WO2007005672A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260284A (en) * | 1987-02-17 | 1993-11-09 | Board Of Regents, The University Of Texas System | Methods employing unique mixtures of polar and neutral lipids and sterol for lung surfactant replacement therapy |
EP0406998A2 (en) * | 1989-03-15 | 1991-01-09 | Board Of Regents, The University Of Texas System | Use of phospholipids in lung surfactant replacement therapy |
US20020099033A1 (en) * | 1997-04-16 | 2002-07-25 | Wisconsin Alumni Research Foundation | Method and composition for treating sleep apnea |
WO2003035679A2 (en) * | 2001-10-25 | 2003-05-01 | Medical Research Council | Molecules |
WO2003090682A2 (en) * | 2002-04-25 | 2003-11-06 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
WO2005055994A1 (en) * | 2003-12-04 | 2005-06-23 | The Scripps Research Institute | Treatment and preventions of asthma |
Also Published As
Publication number | Publication date |
---|---|
WO2007005672A2 (en) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007005672A3 (en) | Treatment and prevention of respiratory diseases and conditions | |
WO2006119329A3 (en) | Compositions and methods for the treatment of neurodegenerative diseases | |
WO2007101551A3 (en) | Phospholipid complexes of curcumin having improved bioavailability | |
WO2006045096A3 (en) | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases | |
WO2006024018A3 (en) | Compositions for treating nociceptive pain | |
WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
WO2005085266A8 (en) | Macrocyclic compounds and methods of making and using the same | |
WO2006020040A3 (en) | Apolipoprotein a1 mimetics and uses thereof | |
WO2007008529A3 (en) | Celullar cholesterol absorption modifiers | |
WO2005105113A3 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
WO2006127757A3 (en) | Interferon-igg fusion | |
PL1799231T3 (en) | Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases | |
WO2007127841A3 (en) | Compositions and methods of preparation thereof | |
WO2008049000A3 (en) | Combination therapy for pulmonary arterial hypertension | |
WO2008002591A3 (en) | Methods for treating atherosclerosis | |
WO2007092622A3 (en) | Compositions and methods for treating bone | |
WO2007095288A3 (en) | Methionine-containing protein or peptide compositions and methods of making and using | |
WO2005118511A3 (en) | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | |
WO2008081934A1 (en) | Agent for facilitating the development of brain in infant comprising milk-derived phospholipid and food composition comprising the same | |
MY147247A (en) | Organic compounds and their uses | |
WO2008143633A3 (en) | Compounds and methods for treatment of alpha-1 antitrypsin deficiency | |
WO2007109037A3 (en) | Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids | |
WO2009015314A3 (en) | Modified lecithin-cholesterol acyltransferase enzymes | |
WO2006128041A3 (en) | Compositions and methods for the treatment or prevention of chemoresistant neoplasia | |
WO2006091542A3 (en) | Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06786042 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06786042 Country of ref document: EP Kind code of ref document: A2 |